

23 April 2026

Hem A, Hem B, and vWD

In Q1 2026 (January, February, March 2026), how many haemophilia A and B and von Willebrand patients were treated with the following coagulation factors in your trust and how much volume (IUs or mg) was used?

Brand name	Number of treated patients	Volume used (IUs, mg)
Hemlibra (non-inhibitor patients)		
Hemgenix		
Altuvoct		
Advate		
Adynovi		
Elocta		
Esperoct		
NovoEight		
ReFacto AF		
Nuwiq		
Hympavzi		
Idelvion		
Refixia		
Alprolix		
BeneFIX		
Replenine		
Rixubis		
Veyvondi		
Voncento		
Wilate		
Willfact		

We supply treatment in line with the National Framework and report all diagnosis, treatments and regimes on a quarterly basis to the National Haemophilia Database provided by the UKHCDO. Any individual/company can apply to the National Haemophilia Database for this information.